-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

SCI-33 Understanding and Targeting Spliceosomal Gene Mutations in Leukemia

Program: Scientific Program
Session: RNA in Normal and Malignant Hematopoiesis
Hematology Disease Topics & Pathways:
Leukemia, AML, Diseases, CLL, CML, Non-Biological, CMML, Therapies, MDS, MPN, Biological Processes, Polycythemia vera, Technology and Procedures, thrombocythemia, epigenetics, Lymphoid Malignancies, Myeloid Malignancies, genomics, genetic profiling, immune mechanism, RNA sequencing, pathogenesis, pathways, signal transduction
Saturday, December 5, 2020, 11:55 AM-12:00 PM

Omar Abdel-Wahab, MD

Memorial Sloan Kettering Cancer Center, New York, NY

Disclosures: Abdel-Wahab: Merck: Consultancy; Envisagenics Inc.: Current equity holder in private company; H3 Biomedicine Inc.: Consultancy, Research Funding; Janssen: Consultancy.

OffLabel Disclosure: I will likely discuss the use of splicing modulatory compounds as well as oligonucleotides in the treatment of hematologic malignancies.